.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
UBS
Citi
Cipla
Accenture
Queensland Health
Fuji
Teva
Express Scripts
Deloitte

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title: Process for reducing intraocular pressure
Abstract:Process and composition for reducing intraocular pressure and reducing aqueous humor formation by applying topically to the cornea an effective amount of an aqueous solution of a caronic anhydrase inhibitor comprising a sulfonamide having the following properties: a. sufficiently soluble in water to form at least a 3 mM solution at pH 8.2 or a pKa of not greater than 7.3; b. ether partition coefficient of at least 1.0; c. chloroform partition coefficient of at least 0.01; d. dissociation constant against carbonic anhydrase of not more than 3.times.10.sup.-8 molar; e. first order rate constant for penetration of the sulfonamide through a living rabbit cornea of at least 0.005 hr.sup.-1 ; f. not injurious to the cornea; and g. stable in aqueous solution and in contact with the cornea.
Inventor(s): Maren; Thomas H. (Gainesville, FL)
Assignee: University of Florida (Gainesville, FL)
Application Number:06/729,907
Patent Claim Types:
see list of patent claims
Use; Formulation; Process; Composition; Dosage form;

No matches for this query

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark376281► Subscribe
Germany3411104► Subscribe
European Patent Office0044134► Subscribe
Ireland811235► Subscribe
France2560769► Subscribe
United Kingdom8406180► Subscribe
United Kingdom2155331► Subscribe
Greece74616► Subscribe
Switzerland659585► Subscribe
Germany3170818► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
Daiichi Sankyo
Boehringer Ingelheim
Express Scripts
US Army
Fuji
UBS
Colorcon
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot